

AN EXPERIENCED TEAM

CELLforCURE, a growing company, currently employs **70 people**, among which 10 hold a PhD in Pharmacy. The teams gather experts in advanced therapy products, as well as men and women specifically trained in the manufacture of cell and gene therapy products, specialists in quality control of biopharmaceuticals, able to manage closed systems that are essential to the manufacture of advanced therapy products for the market, at an industrial scale.

CELLforCURE, a company of the LFB group, is chaired by Léopold BERTÉA. .

Léopold BERTEA was appointed in September, 2015 as Executive Vice President of LFB BIOTECHNOLOGIES, subsidiary of LFB group, head of the new Global Bioproduction Division, and member of the LFB group Executive Committee. He is currently responsible for all non-plasma bioproduction activities at Group level. For more than 20 years Léopold BERTÉA is recognized in pharmaceutical industry for its expertise in biopharmaceutical production and development. First with Novartis, he was in charge of commercial monoclonal antibody production, and before with Sanofi where he built up and led the first integrated Biologics CMC Platform. Léopold BERTEA then covered roles as Vice President Bio-business & Governance for Sanofi's Global Biotherapeutics in charge of the company's biologics pipeline including collaboration projects with partners. He was also a member of the Sanofi global R&D Leading team and a senior Biologics Expert. Holding a PhD in Chemical Engineering from ETH Zürich, he has been CEO of CELLforCURE since July 2017.

